Navigation Links
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Date:6/1/2011

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /PRNewswire/ -- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing. In preclinical studies, in vivo and in vitro activity has been demonstrated against multiple tumor types, including those resistant to other anti-cancer agents.

The NKP-1339 Phase I trial is a dose-ascending trial and determines the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of NKP-1339. A total of 16 patients with metastatic solid tumors resistant to standard therapies have been treated to date at six different dose levels. NKP-1339 treatment has been generally well tolerated, with the most common drug related side effects of grade 1-2 fever and mild flu-like symptoms. MTD has not been reached and NKP-1339 dose escalation continues. Signs of anti-tumor activity (stable disease greater than or equal to four months; tumor regression) have been observed. A patient with a neuroendocrine tumor (NET) of the small intestine has been on NKP-1339 therapy for over 13 months with a continuing minor response. The patient remains on NKP-1339 therapy. Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.

The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Translational Genomics Institute, Arizona, and Dr. Howard Burris, Sarah Canon Research Institute, Tennessee. Reflecting on NKP-1339's novel mechanism of action, Dr. Von Hoff noted "Resistance to anti-cancer therapy remains a major challenge in treatment of patients with metastatic cancer. First-
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
3. Novel Device Shows Promise for Reducing HIV Among Men
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
6. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
7. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, ... Growth, Trends and Forecast, 2013-2019" the global endoscopy devices ... and is expected to grow at a CAGR of ... value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... NATICK, Mass., March 29, 2011 Boston Scientific Corporation ... trial news and events schedule at the 60th Annual ... April 2-5, 2011 in New Orleans. "Twelve-month ... important data on our next-generation PROMUS Element™ Everolimus-Eluting Platinum ...
... 2011 Tris Pharma, Inc., a specialty pharmaceutical company, ... Iron product line.  Since the 2007 launch ... of pediatricians, pediatric nurses and mothers.  When the previous ... different direction, availability of MyKidz Iron™ became limited, but ...
Cached Medicine Technology:Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 2Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 3
(Date:7/11/2014)... 11, 2014 Los Angeles dental ... he uses mini and full mouth implants to replace ... feature that distinguishes dental implants from other tooth replacements: ... the crowns. This alone prevents the long-term complications of ... advantages related to comfort, appearance and systemic health. Mini ...
(Date:7/11/2014)... Maureen Salamon HealthDay Reporter ... the millions of women who can,t cough, sneeze or ... treatment that uses stem cells to regenerate weakened urethra ... found that injecting stem cells isolated from patients, own ... participants within a year. Stress incontinence affects ...
(Date:7/11/2014)... 11, 2014 Recent research findings regarding Fourth ... atmosphere, and how water affects human bodies. That was the ... during an interview on the Sharon Kleyne Hour Power of ... , Gerald Pollack, PhD, is a Professor of Bioengineering at ... Phase of Water (Ebner & Sons, 2013). , ...
(Date:7/11/2014)... WA (PRWEB) July 11, 2014 Shoulder ... the rate of return to play has not been ... the American Orthopaedic Society for Sports Medicine’s ( AOSSM ... NFL players is approximately 90 percent no matter what ... highlighted the success rate of return to play following ...
(Date:7/11/2014)... (ACL) reconstructions occur more than 200,000 times a year, ... new ligament may determine how long you stay in ... the Annual Meeting of the American Orthopaedic Society of ... highlight that in a young athletic population, allografts (tissue ... autografts (tissue harvested from the patient)," said Craig R. ...
Breaking Medicine News(10 mins):Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 3Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 2Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 3Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL reconstructions may last longer with autografts 2
... forced migrations, refugee crisis, large-scale rape of women in sub-Saharan ... that area is a myth. This is according to a ... published this week in the British medical journal The Lancet. ... conflict spread HIV infection in host communities; the reverse may ...
... that regular vaccination of infants against H. influenzae type ... and meningitis, could save innumerable children in Asia. ... online in The Pediatric Infectious Disease Journal, has established ... vaccine prevented more than one-third of acute pneumonia cases ...
... found that a new type of engineered drug may have ... ,The study by researchers at the Ohio State University Comprehensive ... ,The research has established that an engineered drug ... tube and early animal tests. ,The agent ...
... Abuse and Alcoholism (NIAAA), a part of the U.S. ... subtypes of alcoholism by analysing a national sample ... findings should help dispel the popular notion of the ... NIAAA Associate Director for Clinical and Translational Research. ...
... Anxiety disorders seem to afflict humans very early, not sparing even ... for anxiety disorders in New South Wales in Australia. ... figures released by Macquarie University's Anxiety Research Unit show. ... per cent compared to a rate of about 1 per ...
... revealed that the secret of his relatively wrinkle-free visage at the ... ,The slender rock star, notorious for his wild ... applies a special cream under his eyes in order to keep ... the Daily Express quotes him as saying. ,"I ...
Cached Medicine News:Health News:War Spreading AIDS a Myth-UNHCR 2Health News:Routine Hib Vaccination Could Save Innumerable Asian Children 2Health News:Routine Hib Vaccination Could Save Innumerable Asian Children 3Health News:New Engineered Drug Shows Promise in Treating Lymphocytic Leukaemia 2Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 2Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 3Health News:Anxiety Disorders Show in Tiny Tots 2
Idophor PVP Scrub Winged Sponges...
Triad Plus PVP-I Scrub Winged Sponges...
... preoperative skin preparation an ... site infections. Scrub Care brand ... offer high efficacy and safety ... Prevail-Fx offers the highest level ...
Single-dose applicator. Provides a superior, hands-off "friction scrub," enhancing the efficacy of the antiseptic solution it delivers....
Medicine Products: